melanoma

send to a friend share this

Effects of Adipocyte Secretome in Melanoma Progression

Effect of Adipocyte Secretome in Melanoma Progression Obesity is a risk factor for several types of malignancies, leading to worsened prognosis, poorer treatment outcome and an increase in cancer-related deaths. There is a positive association between increased body fat and melanoma development and progression, however the implicated mechanisms remain unclear.

Efeitos do Secretoma de Adipócitos na Progressão do Melanoma

A obesidade é um fator de risco para vários tipos de neoplasias, conduzindo a um pior prognóstico, menor sucesso do tratamento e ao aumento das mortes relacionadas com cancro. Existe uma associação positiva entre o aumento da gordura corporal e o desenvolvimento/progressão do melanoma, no entanto, os mecanismos envolvidos ainda não estão completamente esclarecidos.

Ipilimumab and Vemurafenib: Two promising therapies against melanoma

Melanoma, a malignant tumor of melanocytes, causes the majority (75%) of all skin cancer-related deaths. The overall efficacy of different anti-cancer therapies on metastatic melanoma is quite limited, due to its high resistance to all forms of conventional treatments, including chemotherapy, radiotherapy and immunotherapy, leading to low patient survival rates. The present review identifies possible strategies for the treatment of advanced melanoma and describes two novel agents, Ipilimumab and Vemurafenib, which may now be useful for clinical practice.

Ipilimumab and Vemurafenib: Two promising therapies against melanoma

Melanoma, a malignant tumor of melanocytes, causes the majority (75%) of all skin cancer-related deaths. The overall efficacy of different anti-cancer therapies on metastatic melanoma is quite limited, due to its high resistance to all forms of conventional treatments, including chemotherapy, radiotherapy and immunotherapy, leading to low patient survival rates. The present review identifies possible strategies for the treatment of advanced melanoma and describes two novel agents, Ipilimumab and Vemurafenib, which may now be useful for clinical practice.